Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02440464 · ClinicalTrials.gov registry record · Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

A Phase 2 study of Multiple Myeloma, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
Phase 2
Development phase
57
Enrollment target
15
Study locations

NCT02440464 is a Phase 2 study of Multiple Myeloma that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 57 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 15 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02440464, a Phase 2 study of Multiple Myeloma, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
Phase 2
Development phase
57 participants
Enrollment target
15
Study locations

Study Summary

This study is designed to compare progression-free survival (PFS) from randomization among patients randomized on the BMT CTN 1302 protocol, "Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma". It is hypothesized that Ixazomib maintenance therapy will result in improved PFS in patients with high-risk multiple myeloma following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) compared to placebo.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Fludarabine
  • DRUG Melphalan
  • DRUG Bortezomib
  • PROCEDURE Allogeneic HSCT
  • DRUG Ixazomib

Study Locations (15)

Georgia

  • Emory University - Atlanta
  • BMT Northside - Atlanta

Wisconsin

  • University of Wisconsin Hospital & Clinics - Madison
  • Medical College of Wisconsin - Milwaukee

Alabama

  • University of Alabama - Birmingham

California

  • City of Hope National Medical Center - Duarte

Florida

  • H. Lee Moffitt Cancer Center - Tampa

Illinois

  • Loyola University Medical Center - Maywood

Kentucky

  • University of Kentucky - Lexington

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2015-08
Est. Completion 2020-10-01
Phase Phase 2

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

501 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02440464

The ClinicalTrials.gov registry entry for NCT02440464 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.

NCT02440464 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Georgia, Wisconsin, Alabama.

Frequently Asked Questions

What is clinical trial NCT02440464 about?

NCT02440464 is a clinical study titled "Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)". This study is designed to compare progression-free survival (PFS) from randomization among patients randomized on the BMT CTN 1302 protocol, "Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Mul...

What is the current status of trial NCT02440464?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2015-08. Estimated completion is 2020-10-01.

What conditions does trial NCT02440464 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT02440464?

The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Bortezomib (DRUG), Allogeneic HSCT (PROCEDURE), Ixazomib (DRUG).

Who is sponsoring clinical trial NCT02440464?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02440464 being conducted?

This trial has 15 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.